Diligence memo · auto-generated · as of July 3, 2026
Blue Note Therapeutics, Inc.
Blue Note Therapeutics, Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Blue Note Therapeutics, Inc. operates in Pharma, based in SAN FRANCISCO.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Blue Note Therapeutics, Inc. has raised $13M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $15M on 2021-02-01.
Most recent recorded round closed around 2021-02-01.
Valuation (modeled)modeled
Provath models Blue Note Therapeutics, Inc. at approximately $309M (range $15M–$1.5B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.62× the median modeled value of Series A Pharma companies in 2019–2021 (24 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 5.4 yr ago; this sector typically re-raises about every 16 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 69% of Pharma peers (310 compared).
Modeled value ranks above 81% of those peers.
Closest niche peers: Comet Therapeutics, Inc., RadImmune Therapeutics, Inc., Nanoscope Therapeutics, Inc., ZebiAI Therapeutics, Inc., Vibliome Therapeutics, Llc.
Peoplefiled
3 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.